Highlights
• The European Medicines Agency validates and accepts for review a Marketing application for ORPATHYS plus TAGRISSO.
• Japan's Ministry of Health, Labour and Welfare accepts a New Drug Application for the same lung cancer combination.
• Filings rest on the SAFFRON Phase III trial, which showed improved progression-free and overall survival against chemotherapy.
• AstraZeneca, HUTCHMED's partner, submitted both applications after filing a US New Drug Application in September 2026.
Regulators in Amsterdam and Tokyo now have the dossier on their desks. HUTCHMED (LSE:HCM) told the London Stock Exchange at 07:00 on 2 November 2026 that applications for ORPATHYS (savolitinib) combined with AstraZeneca's TAGRISSO (osimertinib) have been accepted for review in Europe and Japan. The pairing targets lung cancer that has become resistant to TAGRISSO through MET overexpression or amplification, a patient group the two companies have been chasing through a global Phase III trial.
What HUTCHMED announced
The European Medicines Agency has validated and accepted for review a Marketing Authorisation Application submitted by AstraZeneca. In Japan, the Ministry of Health, Labour and Welfare has accepted a New Drug Application, also filed by AstraZeneca.
The European filing covers locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with MET overexpression or amplification, after progression on or after EGFR tyrosine kinase inhibitor (TKI) therapy. The Japanese filing covers unresectable, advanced or recurrent NSCLC with the same MET characteristics following EGFR TKI treatment. Acceptance means the applications are under assessment; no approval has been granted in either region.
The SAFFRON data behind the filings
Both applications are based on SAFFRON, a randomised, open-label global Phase III trial run at 230 centres in 29 countries. It enrolled 338 patients whose disease had progressed on first- or second-line TAGRISSO and compared ORPATHYS plus TAGRISSO with platinum-based doublet chemotherapy.
Median progression-free survival was 7.6 months against 5.4 months, a hazard ratio of 0.55. Median overall survival was 17.8 months against 12.9 months, a hazard ratio of 0.68. At 12 months, 36% of patients on the combination were alive without progression, against 10% on chemotherapy. The results were presented at a Presidential Symposium at the ESMO Congress 2026 and published in a peer-reviewed medical journal.
Partnership context and the US filing
ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and commercialised by AstraZeneca. AstraZeneca submitted a US New Drug Application to the Food and Drug Administration in September 2026. At that point, acting chief executive and chief financial officer Johnny Cheng said: "This filing is an important step toward potentially bringing ORPATHYS® plus TAGRISSO® to patients in the US".
In China, the combination is already approved for EGFR mutation-positive non-squamous NSCLC with MET amplification after EGFR TKI progression, based on the SACHI Phase III trial. ORPATHYS also holds Chinese approvals in MET exon 14 skipping NSCLC and, conditionally, in MET-amplified gastric cancer.
Risks and open points
Regulatory review does not ensure approval, and no decision timetable for Europe or Japan was disclosed. The US application's acceptance status was not stated.
Safety will also be scrutinised. In SAFFRON, grade 3 or higher adverse events occurred in 64% of patients on the combination and 63% on chemotherapy, while discontinuation of any study treatment because of adverse events was 14% against 8%. Twelve patients (7%) in the combination arm had fatal adverse events, against none on chemotherapy; in nine of these, progression was documented before death or cited as the cause.
What investors may watch next in AIM healthcare stocks
The next milestones are progress on the US filing, any questions raised by European and Japanese reviewers, and final regulatory decisions. HUTCHMED, which is quoted on AIM and Nasdaq under HCM and on the Hong Kong Stock Exchange under 13, has also announced a US Orphan Drug designation for sovleplenib and the closing of its KRAS-EGFR antibody licensing deal with GSK in recent weeks. For UK shares in the biotech space, the ORPATHYS reviews now sit alongside those pipeline updates as markers to follow.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...